RE: Adam’s thoughts19 Jul 2023 09:28
Adam Hargreaves post on twitter.
Huge congratulations to the @Inaphaea and @valirxplc teams. The first contract is the hardest, and it has landed. Biotech companies are crying out for two things; 1: Good data, and 2: Reliable and approachable accompanying scientific expertise.
The new lab will provide both. This approach wins customers and contracts. In the second strand of the business, VAL301 and CLX001 now land internally, saving time and money, as they continue their preclinical development.
New VAL compounds and external pharmaceuticals can now also be trialled on both traditional platforms, and in a industry-unique spectrum of patient-derived cancer cells, which is a niche offering and excellent resource to fortify internal/external pipelines.